Compare Stocks: CMPX, MLTX, ALVO, and ABSI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.93 +7.6%	$8.57	$2.24 ▼ $12.06	$1.39B	2.35	3.06 million shs	2.19 million shs
ALVO Alvotech	$3.81 +0.3%	$3.61	$2.94 ▼ $9.25	$1.15B	0.18	814,003 shs	342,028 shs
CMPX Compass Therapeutics	$2.15 +8.0%	$2.09	$1.61 ▼ $6.88	$387.19M	0.92	2.66 million shs	3.83 million shs
MLTX MoonLake Immunotherapeutics	$18.26 +1.3%	$19.05	$5.95 ▼ $62.75	$1.34B	1.06	959,442 shs	902,057 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+7.59%	+14.78%	-19.55%	+51.36%	+207.40%
ALVO Alvotech	+0.26%	-7.52%	+12.06%	+16.87%	-54.96%
CMPX Compass Therapeutics	+8.04%	+12.57%	-8.12%	+17.49%	-26.12%
MLTX MoonLake Immunotherapeutics	+1.28%	-0.98%	-4.25%	+7.03%	-65.39%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABSI Absci	$8.93 +7.6%	$8.57	$2.24 ▼ $12.06	$1.39B	2.35	3.06 million shs	2.19 million shs
ALVO Alvotech	$3.81 +0.3%	$3.61	$2.94 ▼ $9.25	$1.15B	0.18	814,003 shs	342,028 shs
CMPX Compass Therapeutics	$2.15 +8.0%	$2.09	$1.61 ▼ $6.88	$387.19M	0.92	2.66 million shs	3.83 million shs
MLTX MoonLake Immunotherapeutics	$18.26 +1.3%	$19.05	$5.95 ▼ $62.75	$1.34B	1.06	959,442 shs	902,057 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABSI Absci	+7.59%	+14.78%	-19.55%	+51.36%	+207.40%
ALVO Alvotech	+0.26%	-7.52%	+12.06%	+16.87%	-54.96%
CMPX Compass Therapeutics	+8.04%	+12.57%	-8.12%	+17.49%	-26.12%
MLTX MoonLake Immunotherapeutics	+1.28%	-0.98%	-4.25%	+7.03%	-65.39%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABSI Absci	2.78	Moderate Buy	$13.43	50.38% Upside
ALVO Alvotech	2.00	Hold	$7.60	99.48% Upside
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	447.41% Upside
MLTX MoonLake Immunotherapeutics	2.41	Hold	$24.21	32.61% Upside

Current Analyst Ratings Breakdown

Latest CMPX, MLTX, ALVO, and ABSI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/20/2026	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00
7/17/2026	ABSI Absci	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/2/2026	ABSI Absci	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $17.00
7/1/2026	CMPX Compass Therapeutics	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$5.00
7/1/2026	MLTX MoonLake Immunotherapeutics	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$24.00 ➝ $29.00
6/25/2026	ABSI Absci	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Positive	$10.00
6/25/2026	ABSI Absci	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$8.00 ➝ $16.00
6/24/2026	ABSI Absci	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$7.00 ➝ $11.00
6/24/2026	ABSI Absci	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $13.00

(Data available from 8/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABSI Absci	$2.80M	497.21	N/A	N/A	$1.26 per share	7.09
ALVO Alvotech	$588.90M	1.95	$0.22 per share	17.48	($0.94) per share	-4.05
CMPX Compass Therapeutics	$850K	455.52	N/A	N/A	$1.11 per share	1.94
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$4.27 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABSI Absci	-$115.18M	-$0.83	N/A	N/A	N/A	-6,450.76%	-66.32%	-57.01%	8/11/2026 (Estimated)
ALVO Alvotech	$27.92M	-$0.25	N/A	11.91	N/A	-14.36%	-11.92%	-7.59%	8/19/2026 (Estimated)
CMPX Compass Therapeutics	-$66.49M	-$0.41	N/A	N/A	N/A	N/A	-37.16%	-33.59%	N/A
MLTX MoonLake Immunotherapeutics	-$227.32M	-$3.87	N/A	N/A	N/A	N/A	-85.15%	-60.52%	8/11/2026 (Estimated)

Latest CMPX, MLTX, ALVO, and ABSI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/19/2026	Q2 2026	ALVO Alvotech	-$0.0526	N/A	N/A	N/A	$103.00 million	N/A
8/11/2026	Q2 2026	ABSI Absci	-$0.15	N/A	N/A	N/A	$0.89 million	N/A
8/11/2026	Q2 2026	MLTX MoonLake Immunotherapeutics	-$0.9178	N/A	N/A	N/A	N/A	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A
5/11/2026	Q1 2026	MLTX MoonLake Immunotherapeutics	-$0.91	-$0.98	-$0.07	-$0.98	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABSI Absci	N/A	N/A	N/A	N/A	N/A
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABSI Absci	N/A	6.59	6.59
ALVO Alvotech	N/A	1.76	0.88
CMPX Compass Therapeutics	N/A	19.04	19.04
MLTX MoonLake Immunotherapeutics	0.39	8.60	8.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABSI Absci	52.05%
ALVO Alvotech	N/A
CMPX Compass Therapeutics	68.43%
MLTX MoonLake Immunotherapeutics	93.85%

Insider Ownership

Company	Insider Ownership
ABSI Absci	10.52%
ALVO Alvotech	0.46%
CMPX Compass Therapeutics	18.70%
MLTX MoonLake Immunotherapeutics	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABSI Absci	210	155.90 million	139.50 million	Optionable
ALVO Alvotech	1,460	301.81 million	300.42 million	Not Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
MLTX MoonLake Immunotherapeutics	2	73.61 million	65.96 million	Optionable

CMPX, MLTX, ALVO, and ABSI Headlines

Recent News About These Companies

Renaissance Technologies LLC Raises Stake in MoonLake Immunotherapeutics $MLTX

August 6 at 4:32 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX

August 6 at 3:12 AM | marketbeat.com

MLTX stock under pressure as investors await psoriatic arthritis trial data

August 3, 2026 | msn.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Price Down 4.9% - Should You Sell?

August 3, 2026 | marketbeat.com

Why MoonLake Immunotherapeutics’s (MLTX) Stock Is Down 5.02%

August 3, 2026 | aaii.comA

Janus Henderson Group PLC Increases Stock Position in MoonLake Immunotherapeutics $MLTX

August 2, 2026 | marketbeat.com

Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?

July 31, 2026 | zacks.com

Kristian Reich Sells 1,100 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

July 30, 2026 | insidertrades.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Insider Kristian Reich Sells 1,100 Shares of Stock

July 29, 2026 | marketbeat.com

Readystate Asset Management LP Invests $2.69 Million in MoonLake Immunotherapeutics $MLTX

July 29, 2026 | marketbeat.com

Kristian Reich Sells 43,700 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock

July 29, 2026 | insidertrades.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Insider Kristian Reich Sells 43,700 Shares of Stock

July 28, 2026 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Insider Kristian Reich Sells 50,000 Shares

July 28, 2026 | marketbeat.com

MoonLake Immunotherapeutics (MLTX) Projected to Release Earnings on Tuesday

July 28, 2026 | marketbeat.com

Exome Asset Management LLC Purchases Shares of 215,376 MoonLake Immunotherapeutics $MLTX

July 28, 2026 | marketbeat.com

Weiss Asset Management LP Acquires 1,375,367 Shares of MoonLake Immunotherapeutics $MLTX

July 26, 2026 | marketbeat.com

HC Wainwright Issues Positive Estimate for MLTX Earnings

July 22, 2026 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from HC Wainwright

July 20, 2026 | marketbeat.com

MoonLake Immunotherapeutics (NASDAQ: MLTX) - Share Price and Research

July 16, 2026 | intelligentinvestor.com.auI

MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts

July 16, 2026 | marketbeat.com

Moonlake Immunotherapeutics Share Price (MLTX.US)

July 15, 2026 | lse.co.uk

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, MLTX, ALVO, and ABSI Company Descriptions

Absci NASDAQ:ABSI

$8.93 +0.63 (+7.59%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$8.94 +0.01 (+0.12%)

As of 08/7/2026 07:49 PM Eastern

Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to create biologics for patients. Its integrated drug creation platform is designed to improve upon traditional biologic drug discovery by using AI to simultaneously optimize multiple drug characteristics that may be important to development and therapeutic benefit. The company was founded in 2011 and is headquartered in Vancouver, Washington.

Alvotech NASDAQ:ALVO

$3.81 +0.01 (+0.26%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$3.78 -0.03 (-0.79%)

As of 08/7/2026 07:34 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Compass Therapeutics NASDAQ:CMPX

$2.15 +0.16 (+8.04%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$2.12 -0.02 (-1.16%)

As of 08/7/2026 07:45 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

MoonLake Immunotherapeutics NASDAQ:MLTX

$18.26 +0.23 (+1.28%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$18.33 +0.07 (+0.39%)

As of 08/7/2026 07:36 PM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, MLTX, ALVO, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, MLTX, ALVO, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, MLTX, ALVO, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, MLTX, ALVO, and ABSI Company Descriptions

Absci NASDAQ:ABSI

Alvotech NASDAQ:ALVO

Compass Therapeutics NASDAQ:CMPX

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CMPX, MLTX, ALVO, and ABSI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CMPX, MLTX, ALVO, and ABSI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CMPX, MLTX, ALVO, and ABSI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMPX, MLTX, ALVO, and ABSI Company Descriptions

Absci NASDAQ:ABSI

Alvotech NASDAQ:ALVO

Compass Therapeutics NASDAQ:CMPX

MoonLake Immunotherapeutics NASDAQ:MLTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools